At Stago, our focus is on helping laboratories improve efficiency without compromising confidence in their results. That starts with automation through our Max Generation family and extends to digital workflow solutions such as Connect.One and Coag.One that help standardize testing, reduce manual intervention, simplify complex coagulation workflows such as factor and lupus anticoagulant algorithms, and even add automation to lot conversions with our Accreditation Tools. 

Stago’s superpower is our Viscosity-Based Detection System (VBDS), a proven technology that directly measures changes in viscosity during the clot formation rather than relying on optical interpretation. This enables laboratories to deliver reliable results even with challenging samples affected by hemolysis, icterus, and lipemia.

By combining trusted technology, automation, and digital innovation, Stago helps laboratories improve productivity while maintaining the diagnostic confidence clinicians depend on. 

Looking ahead, what emerging technologies, testing needs, or clinical trends do you believe will have the greatest impact on hemostasis diagnostics over the next five years? 

I believe three trends will shape hemostasis over the next five years.

First, laboratories will continue to face workforce shortages while testing volumes grow. Technology must do more than automate; it must help preserve expertise and enable less experienced staff to perform increasingly complex testing with confidence.

Second, digital connectivity will become just as important as instrument performance. Laboratories want systems that integrate seamlessly into enterprise workflows, standardize testing across multiple sites, and provide actionable insights from laboratory data.

Finally, we expect continued growth in specialized coagulation testing as precision medicine expands and clinicians increasingly rely on biomarkers to guide therapy. That creates opportunities for new assays and decision-support tools that improve both diagnostic accuracy and patient outcomes.

The companies that succeed won't simply build better analyzers. They'll build ecosystems that combine instrumentation, software, data, and scientific expertise to help laboratories operate more effectively.

Stago operates in a highly competitive diagnostics market. What do you believe differentiates Stago most in the eyes of laboratory customers, and how are you building on those strengths as the market evolves?

What truly differentiates Stago is that hemostasis isn't one part of our business, it is our business. For nearly 80 years, that singular focus has allowed us to build deep scientific expertise, develop technologies like our Viscosity-Based Detection System (VBDS), and create one of the industry's strongest organizations dedicated exclusively to coagulation diagnostics.

But technology alone isn't what defines us. Our job isn't simply manufacturing coagulation analyzers. Our job is to help laboratories succeed. That means helping our customers navigate workforce shortages, improve operational efficiency, standardize complex testing, and ultimately deliver the highest quality patient care with confidence.

That's why we're investing just as heavily in our people as we are in our products. We continue to strengthen our global service organization, expand our scientific and clinical support, and enhance our digital solutions to help laboratories automate workflows, improve consistency, and make the most of limited staff resources.

As healthcare continues to evolve, our goal isn't simply to provide outstanding instrumentation. We strive to be a trusted partner that laboratories can rely on to solve complex challenges, improve performance, and advance patient care. We believe that long-term partnerships, not just products, are what truly set Stago apart.